X4 Pharmaceuticals (XFOR) Free Cash Flow (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Free Cash Flow of -$15.5 million for Q4 2025, up 44.18% on a QoQ basis from -$27.8 million in Q3 2025, and up 53.03% year-over-year from -$10.1 million in Q4 2024.
X4 Pharmaceuticals (XFOR) Free Cash Flow (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$15.5 million for Q4 2025.
- Quarterly Free Cash Flow rose 53.03% year-over-year to -$15.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$85.6 million (up 48.06% YoY) and the FY2025 annual result came in at -$85.6 million, up 34.76% from the prior year.
- Free Cash Flow was -$15.5 million for Q4 2025 at X4 Pharmaceuticals, up from -$27.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$12.4 million in Q1 2025 and bottomed at -$68.8 million in Q3 2023.
- A 5-year average of -$28.5 million and a median of -$23.4 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow sank 256.2% — and 2025, when it soared 63.25%.
- X4 Pharmaceuticals' Free Cash Flow stood at -$19.1 million in 2021, then declined by 0.32% to -$19.1 million in 2022, then slumped by 45.07% to -$27.7 million in 2023, then declined by 19.06% to -$33.0 million in 2024, then jumped by 53.03% to -$15.5 million in 2025.
- Business Quant data shows XFOR's Free Cash Flow at -$15.5 million in Q4 2025, -$27.8 million in Q3 2025, and -$29.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.95 Mn |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | -15.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.52 Mn |
| Dec 31, 2025 | -15.52 Mn |
| Sep 30, 2025 | -27.80 Mn |
| Sep 30, 2025 | -27.80 Mn |
| Jun 30, 2025 | -29.93 Mn |
| Jun 30, 2025 | -29.93 Mn |
| Mar 31, 2025 | -12.37 Mn |
| Mar 31, 2025 | -12.37 Mn |
| Dec 31, 2024 | -33.04 Mn |
| Dec 31, 2024 | -33.04 Mn |
| Sep 30, 2024 | -34.12 Mn |
| Sep 30, 2024 | -34.12 Mn |
| Jun 30, 2024 | -64.03 Mn |
| Jun 30, 2024 | -64.03 Mn |
| Mar 31, 2024 | -33.66 Mn |
| Mar 31, 2024 | -33.66 Mn |
| Dec 31, 2023 | -27.75 Mn |
| Dec 31, 2023 | -27.75 Mn |
| Sep 30, 2023 | -68.80 Mn |
| Sep 30, 2023 | -68.80 Mn |